Balchem Increases Sales but Misses Revenue Estimate
Balchem (NAS: BCPC) reported earnings on Nov. 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Balchem missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly and GAAP earnings per share was unchanged.
Gross margins grew, operating margins increased, net margins were steady.
Balchem reported revenue of $75.1 million. The three analysts polled by S&P Capital IQ predicted a top line of $77.4 million on the same basis. GAAP reported sales were 0.9% higher than the prior-year quarter's $74.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.36. The three earnings estimates compiled by S&P Capital IQ forecast $0.35 per share. GAAP EPS of $0.36 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 31.1%, 70 basis points better than the prior-year quarter. Operating margin was 21.6%, 120 basis points better than the prior-year quarter. Net margin was 14.5%, about the same as the prior-year quarter.
Next quarter's average estimate for revenue is $73.7 million. On the bottom line, the average EPS estimate is $0.35.
Next year's average estimate for revenue is $306.4 million. The average EPS estimate is $1.33.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 356 members out of 366 rating the stock outperform, and 10 members rating it underperform. Among 83 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 82 give Balchem a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Balchem is outperform, with an average price target of $37.00.
- Add Balchem to My Watchlist.
The article Balchem Increases Sales but Misses Revenue Estimate originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Balchem. Motley Fool newsletter services recommend Balchem. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.